Key result
Among patients with elevated troponin, COVID-19 positivity was associated with higher mortality before discharge and post-discharge.
Why the study?
Elevated troponin predicts in-hospital outcomes in COVID-19, but whether it relates to or predicts longer-term outcomes was unknown.
Does elevated troponin in COVID-19 patients predict long-term mortality compared to COVID-19 negative patients with elevated troponin?
Cohort (n=7,650)
No
Does elevated troponin in COVID-19 patients predict long-term mortality compared to COVID-19 negative patients with elevated troponin?
Elevated troponin levels in patients with COVID-19 are associated with significantly higher in-hospital and long-term post-discharge mortality compared to COVID-19 negative patients with elevated troponin.
Answers are grounded in this paper and cite their sources.
May identify high-risk COVID-19 subgroup for closer monitoring; hypothesis-generating and requires prospective confirmation.
Funding Acknowledgements Type of funding sources: None. Aim Elevated troponin levels have been shown to predict in-hospital outcomes in patients with COVID-19. However, whether this relates to or predicts longer-term outcomes is unknown. We aimed to investigate the effect of troponin elevation in patients with COVID-19, looking at resource utilisation post discharge, re-hospitalisation and outcomes. Methods This was a prospective study of 7650 patients admitted from December 2019 to July 2020 across a large university hospital trust. Patients were stratified according to COVID-19 status and troponin values (elevated = troponin T ≥15 ng/mL). The primary outcome assessed was all-cause mortality. Results 1005 patients were COVID-19 positive and had elevated troponin levels, with the remaining patients troponin positive but COVID-19 negative. COVID+ patients were more likely to be older, and less likely to be Caucasian (35.7% vs 46.6%, p<0.0001), however, peak troponin did not differ significantly between the groups {54 (28-125) vs 47 (25-130) ng/mL, p=0.121}. Mortality before first discharge was four times more likely in COVID+ than COVID- patients with elevated troponins {389 (39%) vs 359 (9.9%); p<0.001}. This mortality rate was also significantly higher than in COVID-19 positive patients who were troponin negative (p=6%, P<0.0001). Post-discharge over a follow-up period of 365 days, in the discharged COVID-19 positive troponin positive group, a minority of patients (13.2%) were investigated with outpatient cardiac investigations (echocardiography, CTCA, coronary angiography and cardiac MRI) compared to the COVID-19 negative group (34.5%). Post-discharge mortality was significantly higher among the COVID+ cohort {63 (10.2%) vs COVID-19 negative troponin positive 103 (3.1%); p<0.001}. COVID+ patients who died post discharge were more likely to be Caucasian (55.4% vs 35.2%, p<0.05) and more likely to be older (81 (72-87.5) vs 67 (57-79), p<0.05) than COVID+ patients who survived post discharge. Conclusion Elevated troponin levels in patients with COVID-19 is associated with long-term mortality. Patients were unlikely to undergo cardiac investigations and the troponin rise likely reflects illness severity. Further data is needed in this area.
No takes yet. Share an insight, caveat, or question.
Deshpande et al. (2022) conducted a cohort in COVID-19 and elevated troponin (n=7,650). COVID-19 infection (in patients with elevated troponin) vs. COVID-19 negative status (in patients with elevated troponin) was evaluated on All-cause mortality (before first discharge) (p=<0.001). Among patients with elevated troponin, COVID-19 positivity was associated with higher mortality before discharge and post-discharge.
Synapse has enriched 10 related papers. Consider them for comparative context: